| Biomarker ID | 1049 |
| PMID | 23356551 |
| Year | 2013 |
| Biomarker | Prostate biopsy clinical decision rule (PBCDR): (HGB+ Age+ PSA+ RBC+Hematuria+ Creatinine+ Black (Ethnicity) + Albumin+ MCV) |
| Biomarker Basis | Concentration Based |
| Biomolecule | Others |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | PC (all stages) vs. non-cancerous conditions |
| Type of Biomarker | Diagnostic |
| Cohort | 616 US Veterans with Prostate Cancer, along with 732 patients categorised as non cancerous (342 Prostatis, 282 BPH, 138 PIN) were chosen for the study. |
| Senstivity | 52.1% |
| Specificity | 74% |
| AUC | 0.68 (95% CI 0.65, 0.71) |
| Accuracy | NA |
| Level Of Significance | p < 0.05 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |